Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study B W Guess1, M C Scholz1, S B Strum2, R Y Lam1, H J Johnson1 and R I Jennrich3 1Prostate Oncology Specialist, Marina del Rey, California, USA 2Medical Oncologist, Ashland, Oregon, USA 3Department of Statistics, University of California at Los Angeles, Los Angeles, California, USA Correspondence to: BW Guess, Prostate Oncology Specialist, 4676 Admiralty Way, Suite 101, Marina del Rey, CA, 90292, USA. E-mail: Brad@prost8cancer.com Abstract This trial investigated the tolerability and effect of modified citrus pectin (Pecta-SolÒ) in 13 men with prostate cancer and biochemical prostate-specific antigen (PSA) failure after localized treatment, that is, radical prostatectomy, radiation, or cryosurgery. A total of 13 men were evaluated for tolerability and 10 for efficacy. Changes in the prostate-specific antigen doubling time (PSADT) of the 10 men were the primary end point in the study. We found that the PSADT increased (P-value<0.05) in seven (70%) of 10 men after taking MCP for 12 months compared to before taking MCP. This study suggests that MCP may lengthen the PSADT in men with recurrent prostate cancer. Prostate Cancer and Prostatic Diseases (2003) 6, 301-304. Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.